Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice
about
The importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseMultiple Aspects of Gene Dysregulation in Huntington's DiseaseDeveloping stem cell therapies for juvenile and adult-onset Huntington's diseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's diseaseAmitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slicesSystemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's diseaseTherapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse ModelHdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's diseaseInhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's diseaseStable G protein-effector complexes in striatal neurons: mechanism of assembly and role in neurotransmitter signaling.Localization of BDNF mRNA with the Huntington's disease protein in rat brain.Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation.A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatumUse of Genetically Altered Stem Cells for the Treatment of Huntington's Disease.BDNF signaling and survival of striatal neurons.Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 miceDifferential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease.ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 miceMesenchymal stem cells for the treatment of neurodegenerative disease.Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.Methyl 3,4-dihydroxybenzoate promotes neurite outgrowth of cortical neurons cultured in vitroHuntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.Huntington's Disease and Striatal Signaling.Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.Disease Modifying Potential of Glatiramer Acetate in Huntington's DiseaseDendritically targeted Bdnf mRNA is essential for energy balance and response to leptinAberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's diseaseBDNF over-expression increases olfactory bulb granule cell dendritic spine density in vivoThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceBDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development.
P2860
Q22306292-F6284F87-EEE1-4590-BD79-A0A4097AB0BBQ24605880-446FE684-C638-4262-AB09-A4953904F40EQ26799722-A8099FEA-45CC-4301-BC48-28205913CDC7Q27005950-4AA18613-73E3-4E42-AC33-7C6B7F97B53CQ27312323-171C668C-1AC4-409D-B918-83DB369C5E54Q27314860-2DDAC82C-9842-45CF-A525-EB226C6814C0Q28241512-4E811E38-1B8E-4641-9F02-B12AEF536E53Q28488296-5E98F855-FC94-48AB-9315-7972037D9F1AQ28546885-1A861238-B55C-499F-8F01-C198245993D7Q28743929-0DF42349-C4BA-417B-A0F4-4F881794880BQ28748849-155BD0C1-D692-4BCA-AA12-3986CF8FA9B0Q30392788-30D072B6-BFE6-4EBD-BF57-09162FAA4F84Q30495033-714A3407-3B94-4BE5-AC87-61300BB4E96AQ33434423-326BAC22-4E11-4F37-8CD2-948A0A1D91A4Q33640604-2829E6EA-9510-4192-8939-86723C7C9B30Q33727623-89C1962A-81B1-4F13-BE29-6E0A298B3ABDQ33763107-D3F60010-D7ED-46D6-911C-4969058A2AC8Q33788929-7D16F598-6D25-46F1-96DA-3EDBA20DDE7DQ34102098-AC593CB8-790B-4893-93C6-65F30A58B19BQ34284039-A3A888EE-C403-4A5E-B81E-EA98E00BAD72Q34338809-7E848E1E-8568-4647-B7D0-668049912706Q34341619-7E9630B0-73DF-4632-8AB4-07143C9E2E76Q34366768-ADB9B2ED-3334-4CB7-BD7E-EF551C3B362BQ34406937-798F3423-AA38-403A-AB6F-8FC81E78DDBCQ34424253-C3823C58-10EA-4DBD-8761-B35CAECEEB7EQ34459323-92A5E2A1-1BD9-4CB8-A359-2EFF0349DFC3Q34473474-C118D74F-F4A2-45B5-82E5-14AC61DF2117Q34505628-19CD402C-2102-471A-B464-FD139A9FBD69Q34583071-6DC04772-C1A4-4F84-ACA0-84B322337D49Q35123777-01155F09-F6AF-4618-922C-387AC120E353Q35158643-D7C7AB52-74D3-4686-9D04-D0F8BFFA8D3AQ35286098-3B3A2B4F-F629-4EC0-9F05-3502173AEC5AQ35487248-144342DF-0167-4021-98A0-4756DB0A22EAQ35782283-B75EA14F-41B3-4EAB-8666-F5E6E21041BAQ35891912-2326036E-3FE0-443D-82C8-77D6A5E0526AQ35897511-C62DA7F7-05C3-4FBE-A6C5-B3DF9AB84465Q35991533-0DF36D7E-0DFC-437F-A2F9-9C1C2DFBDA89Q36037085-8D04DDD3-C3F7-4DE4-9A74-A650EFFB5CB8Q36191786-2A93C333-800B-4021-9669-2532CFB9782EQ36280118-00FEDDF6-180D-42A2-A2D6-20ED70A1B3F1
P2860
Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@ast
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@en
type
label
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@ast
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@en
prefLabel
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@ast
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@en
P2093
P2860
P1476
Brain-derived neurotrophic fac ...... n's disease phenotypes in mice
@en
P2093
Juan Ji An
Kusumika Gharami
P2860
P304
P356
10.1111/J.1471-4159.2007.05137.X
P407
P577
2007-12-12T00:00:00Z